TALTZ Drug Insight

“TALTZ Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about TALTZ for Psoriatic Arthritis (PsA) in the seven major markets. A detailed picture of the TALTZ for psoriatic arthritis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the TALTZ for psoriatic arthritis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the TALTZ market forecast analysis for psoriatic arthritis in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in psoriatic arthritis.

Drug Summary

Ixekizumab is a humanized, IgG4 monoclonal antibody developed by Eli Lilly & Company to treat autoimmune diseases. It was designed to bind IL-17A and produced by recombinant DNA technology in a mammalian cell line. The IL-17A, a proin?ammatory cytokine produced by T helper 17 cells, plays a key role in the pathogenesis of plaque psoriasis and PsA. IL-17A levels are elevated in psoriatic lesions; binding of IL-17A to the IL-17 receptors on keratinocytes leads to the release of other proin?ammatory mediators, which recruit more Th17 cells, neutrophils, dendritic cells, and lymphoid cells. By binding to IL-17A, ixekizumab inhibits its binding to the IL-17A receptor, thereby inhibiting its pro-in?ammatory downstream effects on keratinocytes.

With the trade name TALTZ, ixekizumab has been successively approved for marketing in the US, EU, Canada, Japan, and Australia to treat autoimmune diseases, mainly including plaque psoriasis and PsA (Creative Biolabs, n.d.).

TALTZ is available as an injection for SC use, containing 80 mg/mL of Ixekizumab in a single-dose prefilled autoinjector or syringe. The recommended dose for PsA patients is 160 mg (two 80 mg injections) at Week 0, followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks. For PsA patients with coexistent moderate-to-severe plaque psoriasis, usage of the dosing regimen for adult plaque psoriasis is recommended. It may be administered alone or in combination with a conventional DMARD.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the TALTZ description, mechanism of action, dosage and administration, research and development activities in psoriatic arthritis.
• Elaborated details on TALTZ regulatory milestones and other development activities have been provided in this report.
• The report also highlights the TALTZ research and development activities in psoriatic arthritis across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around TALTZ.
• The report contains forecasted sales of for psoriatic arthritis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for psoriatic arthritis.
• The report also features the SWOT analysis with analyst views for TALTZ in psoriatic arthritis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

TALTZ Analytical Perspective by DelveInsight

In-depth TALTZ Market Assessment

This report provides a detailed market assessment of TALTZ for psoriatic arthritis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

TALTZ Clinical Assessment

The report provides the clinical trials information of TALTZ for psoriatic arthritis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for psoriatic arthritis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence TALTZ dominance.
• Other emerging products for psoriatic arthritis are expected to give tough market competition to TALTZ and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of TALTZ in psoriatic arthritis.
• Our in-depth analysis of the forecasted sales data of TALTZ from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the TALTZ in psoriatic arthritis.

Key Questions

• What is the product type, route of administration and mechanism of action of TALTZ?
• What is the clinical trial status of the study related to TALTZ in psoriatic arthritis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the TALTZ development?
• What are the key designations that have been granted to TALTZ for psoriatic arthritis?
• What is the forecasted market scenario of TALTZ for psoriatic arthritis?
• What are the forecasted sales of TALTZ in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available and how are these giving competition to TALTZ for psoriatic arthritis?
• Which are the late-stage emerging therapies under development for the treatment of psoriatic arthritis?